Compare OCSL & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCSL | CMPS |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2007 | 2020 |
| Metric | OCSL | CMPS |
|---|---|---|
| Price | $11.85 | $11.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $12.63 | ★ $25.38 |
| AVG Volume (30 Days) | 742.0K | ★ 3.7M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.73% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.63 | $2.25 |
| 52 Week High | $14.77 | $12.48 |
| Indicator | OCSL | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 66.31 |
| Support Level | $11.01 | $5.95 |
| Resistance Level | $13.89 | N/A |
| Average True Range (ATR) | 0.24 | 0.79 |
| MACD | -0.05 | 0.10 |
| Stochastic Oscillator | 27.21 | 79.79 |
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.